Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Zhejiang Hangyu Pharmaceutical Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JMKX003142 Injection | Experimental | Single and multiple doses of JMKX003142 Injection administered intravenously. |
|
| Placebo | Placebo Comparator | Placebo administered intravenously. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JMKX003142 Injection | Drug | JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of the Adverse Events that are related to the single dose treatment | single dose safety single dose safety | From Baseline to Day7 |
| Number of the Adverse Events that are related to the multiple dose treatment | multiple dose safety multiple dose safety | From Baseline to Day12 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yiming Dong, MD | Contact | 021-58306003 | dongyiming@jemincare.com | |
| Haiyan Li, MD | Contact | 010-82266226 | haiyanli1027@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University Third Hospital | Beijing | Beijing Municipality | 100191 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41810128 | Derived | Cui C, Zhu J, Liu Z, Liu J, Huang X, Liu Y, Hu J, Zhang L, Zhang X, Sha Y, Liu D, Li H. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial. Drug Des Devel Ther. 2026 Mar 5;20:583445. doi: 10.2147/DDDT.S583445. eCollection 2026. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days. |
|